Centocor, Inc. et al v. Abbott Laboratories, No. 2:07-cv-00139 (E.D. Tex. May 27, 2009)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

I. Introduction Pending before the court is Abbot Laborator ies, Abbot Bioresearch Center, Inc., and Abbot Biotechnology Ltd.’s (colle ctively, “Abbott”) motion for summary judgment (Dkt. No. 163). In its motion, Abbott assert s that Centocor Ortho Biotech, Inc., and Ne w York University (collectively, “Centocor”) are entitled to a priority date of no earlier than February 4, 1994, with respect to the patents-in-suit, United States Patent Nos. 7,070,775 (“the ‘775 patent”) and 7,276,239 (“the ‘239 patent”).